Clinical Trials Browser

Interventional × Melanoma × selinexor × Clear all

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04768881 2024-08-23

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

Phase 2 Terminated

15 enrolled 15 charts

Dermatologic

Melanoma

NCT02120222 2023-04-04

KPT-330

Phase 1 Completed

8 enrolled

Dermatologic

Melanoma

NCT01607905 2023-01-26

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Phase 1 Completed

192 enrolled 29 charts

CNSDermatologicGastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Glioblastoma, Melanoma, Colorectal Neoplasms